 Preliminary evidence shows that ATRC-101 helps those patients with higher target expression; 8 out of 12 patients 66 who took ATCR-101 with H-score 50 responded. Phase 1b study was updated to recruit higher expression solid tumor patients for ATRC-101, with additional monotherapy and combination data expected in 2nd half of 2022. 